Safety, acceptability, and adherence to dapivirine vaginal ring and oral pre-exposure prophylaxis for HIV prevention in the second trimester of pregnancy: a multicountry, open-label, phase 3b randomised trial
Summary
Background
Pregnant women are at a four times higher risk of HIV per coital act than non-pregnant women. MTN-042/DELIVER was a phase 3b randomised study of dapivirine vaginal ring (DVR) and oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate–emtricitabine to assess safety, adherence, and acceptability when used during pregnancy. Our hypothesis was that both DVR and oral PrEP would be safe and well tolerated when started early in the second trimester and continued until delivery.
March 2026
Click for full info +Full Info:
Resource Type:
Citation:
Authors: Mhlanga, F.G., Szydlo, D.W., Mayo, A.J., Bunge, K., Fairlie, L., Nakabiito, C., Musara, P., Mgodi, N.M., Dadabhai, S., Scheckter, R., Anderson, P.L., Marzinke, M.A., Chappell, C., Gadama, L.A., Richardson, B.A., Piper, J.M., Hillier, S.L.
Health Risks(s):
- HIV
- STI / STD
- Unintended Pregnancy
Product type(s):
- ARVs
- HIVtreatment
- IVR
- MPTs
Topic(s):
- MPTs
- Trials
- Social
Region(s)
- Africa
- Global
Additional Keywords:
PrEP; pre-exposure prophylaxis; Africa; MTN-042/DELIVER; oral PrEP; dapivirine vaginal ring; DVR;